Navigation Links
VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label
Date:3/11/2010

BEDFORD, Mass., March 11 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.  

VisEn's new near-infrared label, VivoTag® 680 XL, adds an additional imaging label to its current portfolio of VivoTag fluorescent dyes which are used to label specific biomolecules and ligands of interest in a wide variety of in vivo and in vitro imaging applications.  The new VivoTag 680 XL is designed for more efficient labeling of target molecules under standard research conditions, and is optimized for in vivo and cell-based imaging performance, including superior brightness, biocompatibility and stability in biologic environments.  The new VivoTag 680 XL is particularly well suited for labeling of non-quenching, targeted or physiologic agents, and imaging in related applications.  The fluorescence wavelength is matched for biological imaging applications on a range of in vitro and in vivo fluorescence systems, including the VisEn FMT 2500™ LX quantitative tomography system, which also has expanded wavelength capabilities to enable simultaneous imaging of up to four agents and different biomarkers of interest in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts.  VisEn offers over 30 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, Annexin-Vivo™, and the FAST™ line of imaging agents including Cat K FAST™ and Cat B FAST™.  VisEn also offers specialized lines of agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes and its NanoSpark® nanoparticles, for customized fluorescence agent labeling.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including cell-based and in vivo imaging applications.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT™) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT™) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.

The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

Back to top

RELATED LINKS
http://www.visenmedical.com

'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
4. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
5. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
6. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
7. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
8. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
9. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 25, 2017 , ... As President Trump challenges the status ... his administration could impact the employee benefits industry. James Slotnick, AVP, Government Relations, ... to make it through Congress. His discussion will focus on the current state ...
(Date:4/25/2017)... ... ... Lake Park Dental is now accepting new patients with crooked teeth who ... the help of this highly-effective, yet convenient system, patients can straighten their teeth and ... pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... the way in unveiling cutting-edge birth defects research related to Zika virus during ... the world’s premier society for this important science. , The Teratology ...
(Date:4/25/2017)... ... ... Chaudhary, MD is committed to providing the highest quality of spine care to all his ... with all my patients to alleviate possible future issues. I am pleased to have you ... and my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary ...
(Date:4/25/2017)... Hollywood, Fl (PRWEB) , ... April 25, 2017 , ... ... than Memorial Regional Hospital, according to a special report in the May issue of ... Hospital its highest quality ranking for results achieved during and after coronary bypass ...
Breaking Medicine News(10 mins):